Learning Objectives:

1. To describe the pathophysiologic basis of HFrEF therapies.

2. To identify the indications and contraindications for HFrEF therapies.

3. To understand optimal dosing regimens for HFrEF therapies.

Session date: 
11/18/2022 - 12:00pm to 1:00pm CST
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Michelle Kittleson, MD, PhD